Investing.com - Arrowhead Pharma reported on Monday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Arrowhead Pharma announced earnings per share of $-0.80 on revenue of $31.57M. Analysts polled by Investing.com anticipated EPS of $-0.42 on revenue of $44.86M.
Arrowhead Pharma shares are down 57% from the beginning of the year and are trading at $28.00 , down-from-52-week-high.
Arrowhead Pharma follows other major Healthcare sector earnings this month
Arrowhead Pharma's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar